Introduction {#s0005}
============

The thyroid hormone (3,3′,5-triiodo-L-thyronin, T~3~), is a central mediator of many physiological processes, including embryonic development, cellular differentiation, metabolism, and regulation of cell growth [@bb0005]. These T~3~-regulated cellular processes are mediated via a genomic effect, requiring the activation of nuclear thyroid hormone receptors (TRs). Two major TR isoforms, TRα1 and TRβ1 have been identified, which are encoded on human chromosomes 17 and 3, respectively, and expressed differently in developing and adult tissues [@bb0010]. Tumor formation is usually caused by tumor cell growth and metastasis, depending on the capacity of tumor cells to recruit their own blood supply. Angiogenesis is essential for human cancer development [@bb0015]. The angiogenic process is balanced by the positive regulator, vascular endothelial growth factor (VEGF) [@bb0020], [@bb0025], [@bb0030], [@bb0035] and the negative regulator, thrombospondin-1 (TSP-1) [@bb0040], [@bb0045], [@bb0050]. Previous studies have shown that thyroid hormone induces sprouting angiogenesis through the PDGF-Akt pathway in hypothyroid mice [@bb0055] and increases the activity of angiotensin II that supports neovascularization and stimulates endothelial cell motility [@bb0060]. Abundance evidence has demonstrated that thyroid status and disease affect tumor formation, growth and metastasis in experimental animals and humans [@bb0005]. The collective findings clearly indicate that the thyroid hormone and its receptor play tumor-promoting roles, although the underlying mechanisms of thyroid hormone-stimulated tumor angiogenesis remain to be established.

The interferon-stimulated gene product of 20 kDa, ISG20, has been identified from oligo microarray and ChIP-on-ChIP analyses. We examined the function of ISG20 involved in angiogenesis using MetaCore pathway analysis. ISG20 is a member of the 3′ to 5′ exonuclease superfamily that includes RNases with specificity for single-stranded RNA, and to a lesser extent, DNA [@bb0065], [@bb0070], [@bb0075], that possesses antiviral activity. Previous studies suggest that ISG20 participates in the cellular response to virus infection, and its antiviral activity is induced by NF-κB and IRF1 activation [@bb0080]. Furthermore, ISG20 promotes angiogenesis [@bb0085], although the underlying mechanism is unclear at present. In the current study, we focused on the mechanism underlying the angiogenesis-promoting activity of ISG20 stimulated by thyroid hormone in liver cancer.

Materials and Methods {#s0010}
=====================

Cell Culture and Preparation of T~3~-Depleted Medium {#s0015}
----------------------------------------------------

The human hepatoma cell lines, HepG2 and SK-Hep1 were purchased from the American Type Culture Collection (Taipei, Taiwan). J7 cell line was obtained from Taiwan Hospital. These cells were authenticated by the Mission Biotech using the Promega StemElite™ ID system (Taiwan). These cells were routinely grown in DMEM supplemented with 10% fetal bovine serum. The HepG2 cell line used in this study was stably transfected with TRα (HepG2-TRα1) or TRβ (HepG2-TRβ1), with HepG2-neo as the control cell line. Serum was depleted of T~3~ (Td) using resin [@bb0090]. Cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO~2~.

Establishment of ISG20-Overexpressing Cells and Determination of the Effects of IL-8 Depletion Using the Lentiviral System {#s0020}
--------------------------------------------------------------------------------------------------------------------------

Human IL-8 shRNA was purchased from the RNAi core center (Academia Sinica, Taiwan). IL-8 shRNA and ISG20 plasmid were cloned into the expression vector pLKO1. The plasmid and lentiviral packaging constructs, pCMV-ΔR8.91 and pMD.G, were cotransfected in Her-293T cells via TurboFect reagent Kit (Fermentas Life science, Waltham, MA). After 24-48 h, viral particles with ISG20 were collected to infect SK-Hep1, and viral particles with shIL-8 used to infect the SK-Hep1-ISG20-overexpressing cell line. After 48 h of incubation, cells were transferred to medium containing puromycin for selection.

Quantitative RT-PCR {#s0025}
-------------------

HepG2-TRα1 and HepG2-TRβ1 cells were seeded into 10 cm diameter dishes and exposed to various treatments for the indicated times, prior to harvesting for RNA extraction. Total RNA was purified using TRIzol reagent (Life Technologies Inc., Carlsbad, CA) according to the supplier's protocol, and cDNA synthesized using a SuperscriptII kit (Life Technologies, Karlsruhe, Germany). Real-time PCR was conducted in 15 μl reaction mixtures containing 25 nM forward and reverse primers and 1×SYBR Green reaction mix (Applied Biosystems, Carlsbad, CA). All reactions were conducted in an ABI PRISM 7500 sequencer (Applied Biosystems, Foster City, CA).

Immunoblotting Analysis {#s0030}
-----------------------

Total cell lysates were analyzed via 8% to 10% (w/v) SDS-PAGE, and the separated proteins transferred to PVDF membranes. After washing in PBST (PBS containing 0.05% \[v/v\] Tween-20), blots were incubated in blocking solution (PBST with 5% \[w/v\] skimmed milk powder) containing primary antibody against ISG20, p-JAK2, JAK2 (GeneTex Inc., Irvine, CA), IL-8 (R&D Systems Inc., Minneapolis, MN), p-STAT3(Y705), STAT3 (Cell Signaling Technology Inc., Danvers, MA), VEGF-A, MMP-9, fascin or actin (Santa Cruz Biotechnology Inc., Dallas, TX) at 4°C overnight. After thorough washing, blots were further incubated with HRP-conjugated secondary antibody dissolved in blocking solution. Signals were detected via chemiluminescence using an ECL kit (Amersham) and recorded on X-ray film. JAK2 inhibitor and STAT3 inhibitor (S31-201) were from EMD Millipore (Darmstadt, Germany) and Merck (Canada).

Chromatin Immunoprecipitation (ChIP) Assay {#s0035}
------------------------------------------

HepG2-TRα1 cells treated with 10 nM T~3~ for 24 h or left untreated were harvested and cross-linked with 1% formaldehyde for 10 min at room temperature in DMEM. Reactions were terminated with the addition of 0.125 M glycine. Subsequently, cell lysates were washed three times with PBS and resuspended in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris (pH 8.0), 0.1% SDS and 0.1% sodium deoxycholate) containing three protease inhibitors (1 mM PMSF, aprotinin, and leupeptin). Cell lysates were sonicated with a Misonix Sonicator 3000 Homogenizer (Mandel Scientific Company Inc., Guelph, ON, Canada) to disrupt chromatin. Sonicated DNA was between 200 and 1000 bp in length. Products were precleared with 60 μl protein A/G agarose (Sigma Chemicals, St. Louis, MO) for 2 h at 4°C. Complexes were immunoprecipitated with anti-TR and anti-IgG antibodies (R&D Systems, Inc., Minneapolis, MN). Enriched targets were hybridized to promoter microarrays (Welgene Biotech, ChIP-on-chip microarray) spanning −8 kb to +2 kb of the transcription start site (TSS) of 35 000 genes. The promoter fragments of target gene containing the TRE region were detected via q-RT-PCR.

Human Angiogenesis Array Kit {#s0040}
----------------------------

Cell culture supernatant was collected from ISG20-overexpressing and control of SK-Hep1 for 24 h. The angiogenic factors secreted in supernatant was measured using angiogenesis array kit (R&D systems, Minneapolis, MN), according to the manufacturer\'s instructions. After thorough washing, blots were further incubated with HRP-conjugated secondary antibody dissolved in blocking solution. Signals were detected via Chemi Reagent Mix and recorded on X-ray film.

ELISA for IL-8 {#s0045}
--------------

Cell culture supernatant was collected from ISG20-overexpressing stable HCCs or cells treated with IL-8 neutralizing antibody for 24 h. IL-8 secreted in the supernatant was measured using the IL-8 ELISA kit (BioLegend, San Diego, CA), according to the manufacturer\'s instructions. Absorbance was read at 450 nm using a microplate reader, and concentrations of IL-8 calculated according to the standard curve generated.

*InVitro* Tube Formation Assay {#s0050}
------------------------------

Matrigel (Corning Inc., Tewksbury, MA) was dissolved at 4°C. Aliquots (100 μl/well) were added to 48-well plates, which were incubated at 37°C overnight. HUVEC cells were resuspended at a concentration of 3x10^4^/100 μl in conditional medium, and 30-50 μg conditional medium of SK-Hep1-, J7-control or -ISG20- overexpressing cells added to each well of a 48-well plate. After 18-20 h of incubation at 37°C, cell capillary-like structure formation of HUVECs was assessed via microscopy and images of each well obtained under a light microscope. The number of tube branches was calculated using MacBiophotonics Image J software.

*InVivo* Matrigel Plug Assay {#s0055}
----------------------------

The matrigel plug angiogenesis assay was adapted from a previously described protocol [@bb0025]. Briefly, four week-old male nude mice were randomized into two groups. Specifically, (1) SK-Hep1- and J7-control, and (2) SK-Hep1- and J7-ISG20- overexpressing cell lines were resuspended at a concentration of 5x10^5^/50 μl cells with Matrigel, and 150 μl aliquots were subcutaneously injected into mice. After 7-14 days, plugs were harvested and the hemoglobin content determined using Drabkin\'s reagent. The remaining plugs were fixed with 4% formaldehyde, embedded in paraffin, and subsequently processed for immunohistochemistry (IHC) staining for the endothelial marker CD31.

*InVivo* Chick Chorioallantoic Membrane (CAM) Assay {#s0060}
---------------------------------------------------

Angiogenic activity was evaluated using the CAM assay, as described previously [@bb0025]. Briefly, fertilized chicken eggs (3 eggs/group) were incubated at 37°C in an 80% humidified atmosphere. On developmental day 8, SK-Hep1-control and SK-Hep1-ISG20-overexpressing cells were resuspended at a density of 2×10^5^ cells/100 μl in Matrigel and placed onto one egg of chick embryo for 4 days. CAMs were subsequently examined via microscopy and photographed. Angiogenesis was quantified by counting the number of blood vessel branches using MacBiophotonics Image J software.

Human HCC Specimens {#s0065}
-------------------

Biopsies of 220 patients diagnosed with HCC were selected for study after informed consent was obtained. All HCC tissue samples and paired adjacent non-tumor liver tissue specimens were obtained by the Chang Gung Memorial Hospital Medical Research Center (IRB103-4866B), and subjected to western blot and q-RT-PCR analyses.

Statistical Analysis {#s0070}
--------------------

Results are presented as mean values ± SD of three independent experiments. Statistical analysis was performed in SPSS version 15 (SPSS Inc., Chicago, IL) using the Mann-Whitney test for two groups and one-way ANOVA, followed by Tukey post-hoc test for two or more groups. Kaplan--Meier survival curves were used to analyze survival outcomes. Recurrence-free survival (RFS) with death as an event was analyzed using the log-rank test. *P* values \<0.05 were considered significant.

Results {#s0075}
=======

T~3~ Positively Regulates ISG20 mRNA and Protein Levels in HCC Cells {#s0080}
--------------------------------------------------------------------

We employed oligo-microarray and ChIP-on-ChIP analyses to identify the genes directly regulated by T~3~ in HepG2-TRα1 cells. The major pathway of TR-binding genes is a set of new blood vessel formation by MetaCore pathway analysis. The top of TR-binding/-regulated gene is ISG20 [@bb0095]. However, its function in angiogenesis is currently unclear. To validate the regulation of ISG20 by T~3,~ we used isogenic HepG2 cell lines stably expressing wild-type TRα1 (HepG2-TRα1) and TRβ1 (HepG2-TRβ1). Cells transfected with empty vector were used as a negative control (HepG2-Neo). Notably, the ISG20 mRNA and protein levels of HepG2-TRα1 and HepG2-TRβ1 cells were enhanced following T~3~ treatment in a time- and dose-dependent manner ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*). Protein expression of ISG20 was additionally determined in SK-Hep1 cells expressing low levels of endogenous TR treated without or with T~3~ for 12-48 h. The ISG20 protein level was marginally increased in SK-Hep1 cells treated with T~3~ ([Figure 1](#f0005){ref-type="fig"}*B*). To further determine whether the thyroid hormone response element (TRE) of ISG20 is directly targeted by TR proteins, the chromatin immunoprecipitation (ChIP) assay was performed. TR and RXR bound to ISG20 promoter fragments were pulled down with C4 and RXR antibodies, respectively, but not IgG antibody ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*A*). GAPDH were used as the negative control. Our results clearly demonstrate that ISG20 is up-regulated by T~3~, and TR binds directly to the ISG20 promoter.

Angiogenic Effects of Thyroid Hormone and ISG20 in Hepatoma Cells {#s0085}
-----------------------------------------------------------------

Previous studies have suggested that T~3~ promotes angiogenesis though the PDGF-Akt pathway [@bb0055]. To examine whether T~3~ induces angiogenesis in liver cancer, the human umbilical vein endothelial cell (HUVEC) *in vitro* model was employed. The conditional medium (CM) from HepG2-TRα1 cell lines treated with 10 nM T~3~ significantly promoted tube formation in HUVECs ([Figure 1](#f0005){ref-type="fig"}*C*). To further confirm T~3~-promoted angiogenesis through ISG20 expression, the CM which was collected from ISG20 depleted- and T~3~ (10 nM) treated-HepG2-TRα1cells suppressed tube formation in HUVECs significantly ([Figure 1](#f0005){ref-type="fig"}*D*). The tube formation was also decreased about 3.5-fold in HepG2-TRα1-shISG20 cells compared to that in shControl cells ([Figure 1](#f0005){ref-type="fig"}*D*). To examine the role of ISG20 in tumor progression or angiogenesis, ISG20 overexpression in SK-Hep1 (SK-Hep1-ISG20) and J7 (J7-ISG20) cell lines was established via the lentivirus-based system ([Figure 3](#f0015){ref-type="fig"}*C*). The CM of overexpressing ISG20, but not control CM, dramatically promoted tube formation in HUVECs ([Figure 1](#f0005){ref-type="fig"}*E*). Tube formation was increased about 6- and 2.5-fold in SK-Hep1- and J7-ISG20 cells, respectively, compared to that in control cells ([Figure 1](#f0005){ref-type="fig"}*E*). Our results indicate that ISG20 is up-regulated by T~3~, supporting its involvement in thyroid hormone-promoted angiogenesis in hepatoma cells.Figure 1T~3~ positively regulates mRNA and protein levels of ISG20 and effects of T~3~ and ISG20 on angiogenesis in hepatoma cells. (A) ISG20 mRNA and (B) protein expression in TR stable cell lines (HepG2-TRα1, HepG2-TRβ1, HepG2-neo control or SK-Hep1) incubated for 12, 24 or 48 h in the absence or presence of T~3~ (10 or 100 nM). Total RNA or protein was isolated and analyzed via qRT-PCR and western blot, respectively. (C) HepG2-TRα1 cells were incubated with T~3~ (10 nM) for 24 h, and conditional medium (CM) was collected. HUVECs were incubated with CM for 16 h, and cell capillary-like structure formation was photographed and counted. (D) HepG2-TRα1-shCtrl and HepG2-TRα1-shISG20 cells were incubated with T~3~ (10 nM) for 24 h, and CMs were collected. HUVECs were incubated with CM for 16 h, and cell capillary-like structure formation was photographed and counted. (E) HUVECs were incubated with CM collected from SK-Hep1- and J7-ISG20 and control cells, and cell capillary-like structure formation in HUVECs was photographed and counted. Data are presented as means ± SD from three independent experiments, each performed in triplicate (\**p* \< 0.05; \*\**p* \< 0.01).Figure 1

Overexpression of ISG20 Significantly Promotes Tumor Angiogenesis *In Vivo* {#s0090}
---------------------------------------------------------------------------

To evaluate whether ISG20 promotes HUVEC-primed angiogenesis *in vivo*, mouse xenograft model Matrigel plug formation or chick embryo CAM assay was conducted. Matrigel mixed with SK-Hep1-ISG20 and J7-ISG20 cells significantly enhanced blood vessel growth. The hemoglobin content of the plug was higher following incubation with ISG20-overexpressing cells, indicating increased hepatoma-related angiogenesis *in vivo* ([Figure 2](#f0010){ref-type="fig"}*A*). Furthermore, SK-Hep1 and J7 cells overexpressing ISG20 induced significantly enhanced CAM angiogenesis ([Figure 2](#f0010){ref-type="fig"}*B*). The hemoglobin content was additionally positively correlated with tumor growth ([Figure 2](#f0010){ref-type="fig"}*C*). Finally, higher expression of CD31, an endothelial marker, was observed in the ISG20-overexpressing cell line from the *in vivo* Matrigel plug formation assay ([Figure 2](#f0010){ref-type="fig"}*D*). On the contrary, CM of ISG20-knockdown HepG2-TRα1 cells under T~3~ addition (10 nM) reduced CAM angiogenesis ([Supplementary Figure 1](#ec0005){ref-type="supplementary-material"}*B*). The results clearly suggest that ISG20 functions to promote HUVEC-primed angiogenesis and tumor growth *in vivo*.

IL-8 is a Major Mediator of ISG20-Promoted Tumor Angiogenesis {#s0095}
-------------------------------------------------------------

To identify the angiogenic factors induced by ISG20 in HCC cells, a human angiogenesis array kit [@bb0100], [@bb0105] was screened using CM from the SK-Hep1-Ctrl and SK-Hep1-ISG20 cell lines. Markedly elevated levels of IL-8 and moderate increases in MMP-9, coagulation factor III (TF) and Amphiregulin (AR), well-known pro-angiogenic factors, [@bb0110], [@bb0115], [@bb0120] were observed in the SK-Hep1-ISG20 cell line, compared to the control cell line ([Figure 3](#f0015){ref-type="fig"}*A*, left panel). Conversely, insulin-like growth factor binding protein-3 (IGFBP-3) and Endostatin (collagen XVIII) levels were reduced upon ISG20 overexpression ([Figure 3](#f0015){ref-type="fig"}*A*, left panel). Endostatin is an endogenous inhibitor of angiogenesis and tumor growth while IGFBP-3 is reported to play a dual role in angiogenesis [@bb0125], [@bb0130]. The quantitative result was shown ([Figure 3](#f0015){ref-type="fig"}*A*, right panel). In view of its marked elevation, we further investigated the role of IL-8 in ISG20-stimulated angiogenesis. Induction of IL-8 by ISG20 using CM from cell lines was confirmed via ELISA. The IL-8 level was significantly higher in SK-Hep1- and J7-ISG20 cells, compared to control cells ([Figure 3](#f0015){ref-type="fig"}*B*). Expression of IL-8 protein was dramatically increased by ISG20 overexpressing in HCC stable cell lines. In addition to angiogenic factors, VEGF-A and MMP-9 protein levels were higher in SK-Hep1- and J7-ISG20 cells, as evident from western blot ([Figure 3](#f0015){ref-type="fig"}*C*). Previous studies have shown that tumor-derived IL-8 activates endothelial cells in tumor vasculature and triggers JAK2 and STAT3 activation (p-JAK2/p-STAT3) to promote angiogenesis [@bb0135]. Notably, in our experiments, CM from ISG20-overexpressing HCC stable cell lines dramatically activated JAK2/STAT3 phosphorylation in HUVECs ([Figure 3](#f0015){ref-type="fig"}*D*). The data collectively support the theory that IL-8 is an important angiogenic factor that contributes to ISG20-promoted angiogenesis through the p-JAK2/p-STAT3 signaling pathway.Figure 2Overexpression of ISG20 significantly promotes tumor angiogenesis *in vivo.* (A) Mice were subcutaneously injected with Matrigel mixed with control or ISG20-overexpressing cells (SK-Hep1 and J7) for 7 days. Plugs excised from mice were photographed (n = 8). (B) ISG20-overexpressing and control cells mixed in Matrigel were placed on chick CAMs, and images of CAM artery branches in groups obtained on developmental day 12 (left panel). Quantification of the microvessel number in the CAM assay (n = 3, right panel). (C) Hemoglobin content in plugs isolated from mice at day 7, measured using Drabkin's procedure. Tumor (plug) volume and weight were measured. (D) Levels of ISG20 and the endothelial marker, CD31, were determined from plugs of ISG20-overexpressing and control cells via IHC staining. Data are presented as means ± SD (\**p* \< 0.05; \*\**p* \< 0.01).Figure 2Figure 3IL-8 is major mediator of ISG20-promoted tumor angiogenesis. (A) Human angiogenesis array membranes were used to analyze secretion of angiogenic growth factors by CM of control and ISG20-overexpressing SK-Hep1 cells (left panel). Quantitative data is shown in the right panel. (B) Determining the expression of the major pro-angiogenic factor, IL-8, in response to ISG20-overexpressing and control SK-Hep1 or J7 cells via ELISA. (C) Western blot analysis of the expression of ISG20 and pro-angiogenic factors, IL-8, VEGF-A and MMP-9, in ISG20-overexpressing or control SK-Hep1 or J7 cells. (D) Expression of p-JAK2 and p-STAT3 in HUVECs incubated with CM of ISG20-overexpressing cells analyzed via western blot. Data are presented as means ± SD (\**p* \< 0.05; \*\**p* \< 0.01).Figure 3

Knockdown of IL-8 Decreases HUVEC-Primed Angiogenesis *In Vitro* {#s0100}
----------------------------------------------------------------

To evaluate whether IL-8 contributes to HUVEC-primed angiogenesis in the microenvironment of liver cancer, IL-8 shRNA stable cell lines were established. An IL-8 neutralizing antibody blocking IL-8 expression in ISG20-overexpressing HCC stable lines was employed to determine whether reduction of IL-8 inhibits angiogenesis in an *in vitro* tube formation assay. IL-8 expression was greatly repressed by an IL-8 specific shRNA ([Figure 4](#f0020){ref-type="fig"}*A*, left panel) or its specific neutralizing antibody ([Figure 4](#f0020){ref-type="fig"}*A*, right panel) in two cell lines. Depletion of IL-8 by its shRNA ([Figure 4](#f0020){ref-type="fig"}*B*) or neutralizing antibody ([Figure 4](#f0020){ref-type="fig"}*C*) in ISG20-overexpressing HCC stable lines strongly abolished ISG20-promoted tube formation in HUVECs. Quantitative data showed a higher number of tubes in control shRNA than IL-8 shRNA of ISG20-overexpressing stable HCC cell lines ([Figure 4](#f0020){ref-type="fig"}*B*, bottom panel). Similar suppression of ISG20-promoted angiogenesis was observed upon IL-8 depletion ([Figure 4](#f0020){ref-type="fig"}*C*, bottom panel). Additionally, phosphorylation of JAK2 and STAT3 signaling proteins in HUVECs were decreased by CM from ISG20-overexpressing stable HCC lines depleted of IL-8 ([Figure 4](#f0020){ref-type="fig"}*D*). Using JAK2 inhibitor or STAT3 inhibitor (S31-201) also dramatically abolished ISG20-promoted tube formation in HUVECs ([Figure 4](#f0020){ref-type="fig"}*E*). The quantitative data was shown ([Figure 4](#f0020){ref-type="fig"}*E*, bottom panel). Additionally, the 13hosphor-JAK2 and STAT3 signaling proteins in ISG20-overexpressing stable HCC lines were decreased by these inhibitors ([Supplementary Figure 2](#ec0010){ref-type="supplementary-material"}). Taken together, the results suggest that ISG20 promotes angiogenesis through enhancing IL-8 expression and JAK/STAT3 activation *in vitro*.

Suppression of IL-8 Eliminates ISG20-Enhanced Tumor Angiogenesis *In Vivo* {#s0105}
--------------------------------------------------------------------------

We additionally investigated whether suppression of IL-8 affects ISG20-enhanced tumor angiogenesis *in vivo* via the Matrigel plug formation and CAM assay. To this end, IL-8 knockdown in ISG20-overexpressing stable lines and plug formation via subcutaneous injection were achieved. More blood vessels were observed and plug size was bigger in control shRNA than IL-8-depleted of ISG20-overexpression stable cell lines ([Figure 5](#f0025){ref-type="fig"}*A*). Moreover, the hemoglobin content of plugs formed from ISG20-overexpressing cells depleted of IL-8 was decreased ([Figure 5](#f0025){ref-type="fig"}*A*). In the CAM assay, formation of new blood vessels was dramatically decreased following IL-8 knockdown in ISG20-overexpressing stable cells ([Figure 5](#f0025){ref-type="fig"}*B*). Finally, CD31 expression in the plug of control shRNA cells was higher than that in the plug of the IL-8 depletion group, as observed with IHC staining ([Figure 5](#f0025){ref-type="fig"}*C*). Based on these findings, we propose that ISG20 promotes IL-8 expression to enhance HUVEC-primed angiogenesis *in vivo*.Figure 4Knockdown of IL-8 decreases HUVEC-primed angiogenesis *in vitro*(A) IL-8 depletion in ISG20-overexpressing cells (SK-Hep1 and J7), observed via western blot (left panel) or in IL-8 neutralizing antibody using ELISA (right panel). (B) CM of IL-8 knockdown or control SK-Hep1- and J7-ISG20 cells was collected, incubated with HUVECs, and cell capillary-like structure formation was photographed and counted. (C) CM of IL-8 neutralizing antibody (0.2 μg/ml) and control antibody-treated SK-Hep1- and J7-ISG20 cells was collected. HUVECs were incubated with CM, and cell capillary-like structure formation was photographed and counted. (D) Western blot analysis of p-JAK2 and p-STAT3 protein expression between HUVECs incubated with CM of IL-8 knockdown and control of ISG20-overexpressing SK-Hep1 or J7 cells. (E) CM of JAK2 inhibitor treated- (100 μM), or S31-201 treated- (100 μM), or DMS0-treated SK-Hep1- or J7-ISG20 cells were collected. HUVECs were incubated with CM, and cell capillary-like structure formation was photographed and counted. Data are presented as means ± SD (\**p* \< 0.05; \*\**p* \< 0.01).Figure 4Figure 5Suppression of IL-8 eliminates ISG20-enhanced tumor angiogenesis *in vivo*. (A) Mice were subcutaneously injected with Matrigel mixed with IL-8 depletion or control vector-containing ISG20-overexpressing cells (SK-Hep1 or J7) for 7 days. Plugs excised from mice were photographed (n = 4) and the hemoglobin content isolated on day 7 was measured using Drabkin's procedure. (B) CM of IL-8 knockdown or control vector-containing ISG20-overexpressing cells mixed in Matrigel were placed on chick CAMs. CAM artery branches in groups were photographed on developmental day 12, and the microvessel number was quantified in the CAM assay (n = 3). (C) Expression of the endothelial marker, CD31, in IL-8 knockdown or control vector-containing ISG20-overexpressing cells was determined from plugs via IHC staining. Data are presented as means ± SD (\**p* \< 0.05; \*\**p* \< 0.01).Figure 5Figure 6ISG20 is highly expressed in human HCC and positively correlated with IL-8 expression in specimens. (A) ISG20, TRα and IL-8 gene expression analysis using the *ONCOMINE* database. (B) Kaplan-Meier analysis of recurrence-free survival based on ISG20 and TR expression levels in 154 paired HCC specimens. Mean expression levels of these genes were used as the cut-off. (C) Pearson correlation of ISG20, IL-8 and TR were analyzed. (D) q-RT-PCR analysis of ISG20 and IL-8 mRNA expression in 220 HCC specimens. (E) Representative western blot image (10 out of 50 = 20%) of ISG20 and TR protein levels between cancerous and matched adjacent tissues were shown. Data are presented as means ± SD (\**p* \< 0.05; \*\**p* \< 0.01).Figure 6

ISG20 is Highly Expressed in Human HCC and Correlated with IL-8 Expression {#s0110}
--------------------------------------------------------------------------

We further investigated the role of ISG20 in liver cancer progression and its correlation with IL-8 in clinical specimens. ISG20 mRNA level was overexpressed in 65.9% (145 out of 220) cancerous tissues, compared to matched adjacent tissues (data not shown). ISG20 expression was additionally analyzed in the web-based microarray database, *ONCOMINE.* High levels of ISG20, TRα1 and IL-8 were detected in HCCs, compared to normal tissues, from the Mas microarray database ([Figure 6](#f0030){ref-type="fig"}*A*). Furthermore, expression of ISG20 and TRα was significantly correlated with recurrence-free survival of HCC patients ([Figure 6](#f0030){ref-type="fig"}*B*). Statistical analysis revealed moderate positive relationships between expression of ISG20, TRα (Pearson's *r* = 0.394, *p* \< 0.005) and IL-8 (Pearson's *r* = 0.334, *p* \< 0.005) in HCCs ([Figure 6](#f0030){ref-type="fig"}*C*). Analysis of the clinicopathological significance of ISG20 and IL-8 expression in 220 paired HCCs revealed that levels of both mRNA were significantly enhanced in relation to vascular invasion (*p* \< 0.05), high α-fetoprotein (AFP) concentration (\>25 ng/ml, *p* \< 0.05), and bigger tumor size (\>5cm, *p* \< 0.05) ([Figure 6](#f0030){ref-type="fig"}*D*). In addition, the potential function of ISG20 is to inhibit the replication of hepatitis C virus [@bb0140]. Thus, we analyzed the relationship between ISG20 expression and HCV infection in HCC specimens. However, the levels of ISG20 didn't correlate with HCV infection ([Supplementary Figure 3](#ec0015){ref-type="supplementary-material"}). Moreover, enhanced TRα and concomitantly elevated ISG20 protein levels were observed in matched cancerous tissues in 20 % cases (10 out of 50; [Figure 6](#f0030){ref-type="fig"}*E*). Based on these results, we conclude that ISG20 expression is higher in HCCs and significantly correlated with IL-8 and TRα.

Discussion {#s0115}
==========

In this study, we focused on characterization of ISG20 identified from oligo microarray screening for T~3~-responsive genes in HepG2-TRα1 cells. The significance of T~3~ modulation of ISG20 in HCC has not been established to date. Our results suggest that ISG20 is positively modulated by T~3~ at both mRNA and protein levels. Data from the ChIP assay revealed that TR proteins directly bind TRE of the ISG20 promoter region. T~3~ has been shown to induce angiogenesis-related proteins, such as VEFG, bFGF and PDGF [@bb0055], leading to promotion of sprouting angiogenesis. In our experiments, CM from T~3~-treated HepG2-TRα1 enhanced angiogenesis in HUVECs, as observed with the tube formation assay *in vitro*. However, the molecular mechanisms of T~3~-induced tumor angiogenesis remain unknown.

Recent studies have demonstrated that ISG20 is an interferon (IFN)-induced gene product with *M*r 20,000 [@bb0145]. ISG20 is a member of the 3′ to 5′ exonuclease family that specifically degrades single-stranded RNA [@bb0150] and, to a lesser extent, DNA, suggesting that ISG20 is a mediator of the innate immune response and potentially involved in the antiviral function of IFN against RNA viruses [@bb0070], [@bb0145]. Moreover, IFN exerts antitumor activity against various human malignancies and appears to suppress angiogenesis through preventing endothelial cell differentiation, and not direct antiproliferative effects. Interestingly, a previous report showed that ISG20 expression is induced by IFN but does not inhibit angiogenesis upon overexpression in HUVECs. Furthermore, a dominant-negative mutant (showing loss of exonuclease activity) of ISG20 suppressed tube formation in HUVECs [@bb0085] via an unknown mechanism. Here, we obtained evidence showing that ISG20 promotes tumor angiogenesis via regulation of IL-8 in HCC cells. Moreover, our findings suggest that ISG20 positively regulates IL-8 expression and activates JAK2/STAT3 phosphorylation in hepatoma cells. IL-8 is reported to enhance angiogenesis through multiple signaling pathways, including JAK2/STAT3, Akt, and Erk1/2 cascades [@bb0135]. However, we did not observe an association between IL-8 overexpression and increased Akt or Erk1/2 expression and activity. The discrepancy between our findings and those reported previously may be due to cell type specificity. Notably, activation of the CXCR2 receptor by IL-8 leads to JAK2-dependent phosphorylation of a member of the signal transducer and activator of transcription family, STAT3, which positively mediates angiogenesis in multiple cancers [@bb0155], [@bb0160]. Recently, Dodd et al. [@bb0165] reported that STAT3 cooperates with mTOR to enhance angiogenesis. Moreover, endothelial progenitor cells activate the JAK2/STAT3 signaling pathway to accelerate angiogenesis [@bb0135].

Thyroid hormone is a critical mediator of diverse cellular functions, including cellular metabolism, proliferation and organ development, in the normal physiological environment [@bb0005]. Recent studies have demonstrated nongenomic actions of thyroid hormone-induced angiogenesis mediated by the cell surface receptor integrin αvβ3 [@bb0170]. Chen et al. [@bb0055] reported that T~3~ enhances PDGF receptor β protein to induce angiogenesis in hypothyroid heart. However, the importance of TR involvement in angiogenesis has not been reported to date. Overexpression of TR and Wnt pathway activation have been shown to promote colorectal cancer formation [@bb0175]. Further evidence has been obtained showing that aberrant and mutant TR play a role in promotion of cancer progression via up-regulation of lipocalin 2 through the MET/FAK signaling pathway to promote HCC metastasis, [@bb0180] and repression of microRNA-130b by T~3~/TR enhances cell motility via up-regulation of epithelial-mesenchymal transition (EMT)-related genes, MMP-9, p-mTOR, p-Erk1/2, p-Akt and p-STAT3, in hepatoma cells [@bb0185]. In the current study, we showed that ISG20 promotes angiogenesis of hepatoma cell lines *in vitro* and *in vivo*, and is positively correlated with vascular invasion and tumor size in HCC tissues.

In conclusion, we have identified a novel mechanism involving ISG20 induction by T~3~ via the IL-8/p-JAK2/p-STAT3 signaling pathway to promote tumor angiogenesis in HCC.

The following are the supplementary data related to this article.Supplementary Figure 1(A) TR binds directly to the ISG20 promoter. (B) Knockdown ISG20 abolished T~3~-enhanced tumor angiogenesis by *in vivo* CAM assay.Supplementary Figure 1Supplementary Figure 2p-JAK2 and p-STAT3 protein levels were decreased by JAK2/STAT3 inhibitors.Supplementary Figure 2Supplementary Figure 3The correlation of ISG20 with HCV infection in clinical HCC specimens.Supplementary Figure 3
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